J 2020

Gadolinium labelled nanoliposomes as the platform for MRI theranostics: in vitro safety study in liver cells and macrophages

SIMECKOVA, Pavlina; Frantisek HUBATKA; Jan KOTOUCEK; Pavlina KNOTIGOVA TURANEK; Josef MASEK et al.

Základní údaje

Originální název

Gadolinium labelled nanoliposomes as the platform for MRI theranostics: in vitro safety study in liver cells and macrophages

Autoři

SIMECKOVA, Pavlina; Frantisek HUBATKA; Jan KOTOUCEK; Pavlina KNOTIGOVA TURANEK; Josef MASEK; Josef SLAVIK; Ondrej KOVAC; Jiri NECA; Pavel KULICH; Dominik HREBÍK; Jana STRASKA; Katerina PENCIKOVA; Jirina PROCHAZKOVA; Pavel DIVIS; Stuart MACAULAY; Robert MIKULÍK; Milan RASKA; Miroslav MACHALA a Jaroslav TURÁNEK

Vydání

Scientific reports, LONDON, NATURE PUBLISHING GROUP, 2020, 2045-2322

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30224 Radiology, nuclear medicine and medical imaging

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 4.380

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/20:00116364

Organizační jednotka

Lékařská fakulta

EID Scopus

Klíčová slova anglicky

HEPARG CELLS; MOLECULAR-MECHANISMS; OXIDATIVE STRESS; GENE-EXPRESSION; CONTRAST AGENTS; DTPA LIPOSOMES; TOXICITY; GRAPHENE; DISEASES; ENZYMES

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 8. 9. 2020 13:44, Mgr. Tereza Miškechová

Anotace

V originále

Gadolinium (Gd)-based contrast agents are extensively used for magnetic resonance imaging (MRI). Liposomes are potential nanocarrier-based biocompatible platforms for development of new generations of MRI diagnostics. Liposomes with Gd-complexes (Gd-lip) co-encapsulated with thrombolytic agents can serve both for imaging and treatment of various pathological states including stroke. In this study, we evaluated nanosafety of Gd-lip containing PE-DTPA chelating Gd+3 prepared by lipid film hydration method. We detected no cytotoxicity of Gd-lip in human liver cells including cancer HepG2, progenitor (non-differentiated) HepaRG, and differentiated HepaRG cells. Furthermore, no potential side effects of Gd-lip were found using a complex system including general biomarkers of toxicity, such as induction of early response genes, oxidative, heat shock and endoplasmic reticulum stress, DNA damage responses, induction of xenobiotic metabolizing enzymes, and changes in sphingolipid metabolism in differentiated HepaRG. Moreover, Gd-lip did not show pro-inflammatory effects, as assessed in an assay based on activation of inflammasome NLRP3 in a model of human macrophages, and release of eicosanoids from HepaRG cells. In conclusion, this in vitro study indicates potential in vivo safety of Gd-lip with respect to hepatotoxicity and immunopathology caused by inflammation.